1.
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-...
by Maertens, Johan A, Prof
The Lancet (British edition), 2016, Vol.387 (10020), p.760-769
2.
Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature
by Sherwin, Jennifer, MD
Clinical therapeutics, 2016, Vol.38 (9), p.1976-1994
3.
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial
by JARVIS, Joseph N
AIDS (London), 2012, Vol.26 (9), p.1105-1113
4.
Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis
by Kyvernitakis, A
Clinical microbiology and infection, 2016, Vol.22 (9), p.811.e1-811.e8
5.
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007
by Skiada, A
Clinical microbiology and infection, 2011, Vol.17 (12), p.1859-1867
6.
Phytogenic synthesis of silver nanoparticles, optimization and evaluation of in vitro antifungal activity against human and plant pathogens
by Balashanmugam, P
Microbiological research, 2016, Vol.192, p.52-64
7.
Antifungal agents and liver toxicity: a complex interaction
by Tverdek, Frank P.
Expert review of anti-infective therapy, 2016, Vol.14 (8), p.765-776
8.
Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation
by Schmidt-Hieber, Martin
Expert review of anti-infective therapy, 2019, Vol.17 (12), p.983-995
9.
Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical Problem
by Arrese, Jorge E
Dermatology (Basel), 2003, Vol.207 (3), p.255-260
10.
Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients
by Ruiz-Gaitán, Alba
Expert review of anti-infective therapy, 2019, Vol.17 (4), p.295-305
11.
Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
by Cadranel, J
European journal of clinical microbiology & infectious diseases, 2012, Vol.31 (11), p.3231-3239
12.
A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital
by López-Medrano, F
Clinical microbiology and infection, 2013, Vol.19 (1), p.56-61
13.
Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial
by Sharma, Savitri
British Journal of Ophthalmology, 2015, Vol.99 (9), p.1190-1195
14.
Comparison of Photodynamic Therapy versus conventional antifungal therapy for the treatment of denture stomatitis: a randomized clinical trial
by Mima, E.G
Clinical microbiology and infection, 2012, Vol.18 (10), p.E380-E388
15.
Breakthrough candidaemia in the era of broad-spectrum antifungal therapies
by Cuervo, G
Clinical microbiology and infection, 2016, Vol.22 (2), p.181-188
16.
Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
by Molloy, Síle F
AIDS (London), 2018, Vol.32 (15), p.2259-2261
17.
Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury
by Cota, Jason M., PharmD
Clinical therapeutics, 2016, Vol.38 (9), p.2016-2031
18.
Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome
by CHANG, Christina C
AIDS (London), 2013, Vol.27 (13), p.2089-2099
19.
Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis
by Ebbens, Fenna A
Journal of allergy and clinical immunology, 2006, Vol.118 (5), p.1149-1156
20.
Antimicrobial Agent Dosing in Infants
by Johnson, Jacob K., MD
Clinical therapeutics, 2016, Vol.38 (9), p.1948-1960
